Browsing Tag
Novartis
83 posts
Novartis dodges Trump’s drug tariff blitz with $23bn US reshoring plan
Find out how Novartis plans to produce all key medicines in the US through a $23B investment in 10 new and expanded facilities nationwide.
Novartis wins FDA approval for Fabhalta, the first treatment for C3 glomerulopathy
Novartis secures FDA approval for Fabhalta, the first-ever treatment for C3G. Find out how this breakthrough impacts patients and investors.
Novartis achieves 22% rise in core operating income, driven by innovative medicines
Novartis has reported a stellar performance for the fourth quarter of 2024, showcasing impressive growth across its core…
Novartis company profile: A global leader redefining healthcare innovation
What is the history of Novartis and its establishment? Novartis emerged in 1996 following the merger of Ciba-Geigy…
Schrödinger stock skyrockets as Novartis invests billions in new partnership
In a landmark development, Schrödinger, Inc. has entered into a multi-target research collaboration and expanded software licensing agreement…
Game-changer for kidney disease: Novartis’ Fabhalta wins FDA approval in record time
Novartis has reached a pivotal moment in the treatment of rare kidney diseases with the US Food and…
Novartis’ atrasentan shows significant reduction in proteinuria in seasonal allergic rhinitis patients
Novartis presented compelling interim results from the Phase III ALIGN study evaluating the efficacy of atrasentan, an investigational…
Novartis to expand oncology portfolio with acquisition of Mariana Oncology
Novartis has announced a significant move in the oncology sector with its agreement to acquire Mariana Oncology, a…
Novartis announces promising long-term data on Kesimpta for relapsing multiple sclerosis
In a significant revelation, Novartis Pharmaceuticals Corporation has announced the latest findings from the ALITHIOS open-label extension study.…
Novartis reports significant proteinuria reduction by Fabhalta in Phase 3 IgAN trial
Novartis has shared encouraging results from the Phase III APPLAUSE-IgAN study, revealing that Fabhalta (iptacopan) led to a…